Reducing immune problems caused by radiation exposure using PrC-210 treatment
Mitigation of Radiation Induced Immune Dysfunction by PrC-210 Treatment
This study is looking at a new treatment called PrC-210 to see if it can help protect the immune system and gut health after someone has been exposed to radiation, like in a nuclear accident, with the hope of improving survival rates.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-11086075 on NIH RePORTER |
What this research studies
This research investigates the use of a novel compound, PrC-210, to mitigate immune dysfunction caused by radiation exposure. The study focuses on understanding how PrC-210 can protect the immune system and gastrointestinal health after radiation events, such as nuclear accidents or attacks. By administering PrC-210 at specific times after radiation exposure, researchers aim to enhance survival rates and uncover the mechanisms behind its protective effects. The approach includes optimizing the delivery of the treatment and evaluating its efficacy in preclinical models.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to radiation due to accidents or disasters.
Not a fit: Patients who have not been exposed to radiation or who have pre-existing severe immune dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that protect patients from the harmful effects of radiation exposure.
How similar studies have performed: Previous studies have shown promising results with similar compounds in animal models, indicating potential for success in this approach.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Kumar, Vidya — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Kumar, Vidya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.